1. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. (26th November 2018) Authors: Adams, S; Schmid, P; Rugo, H S; Winer, E P; Loirat, D; Awada, A; Cescon, D W; Iwata, H; Campone, M; Nanda, R; Hui, R; Curigliano, G; Toppmeyer, D; O'Shaughnessy, J; Loi, S; Paluch-Shimon, S; Tan, A R; Card, D; Zhao, J; Karantza, V Journal: Annals of oncology Issue: Volume 30:Number 3(2019) Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. (26th November 2018) Authors: Adams, S; Loi, S; Toppmeyer, D; Cescon, D W; De Laurentiis, M; Nanda, R; Winer, E P; Mukai, H; Tamura, K; Armstrong, A; Liu, M C; Iwata, H; Ryvo, L; Wimberger, P; Rugo, H S; Tan, A R; Jia, L; Ding, Y; Karantza, V; Schmid, P Journal: Annals of oncology Issue: Volume 30:Number 3(2019) Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗